publication . Article . 2007

We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development.

Rachelle S. Doody;
Restricted
  • Published: 21 Dec 2007 Journal: Alzheimer's & Dementia, volume 4, pages S21-S25 (issn: 1552-5260, Copyright policy)
  • Publisher: Wiley
Abstract
Abstract The terms symptomatic and disease-modifying have become standard in discussions of Alzheimer's disease therapeutics, yet there is little justification for their use. Currently marketed drugs are presumed to be symptomatic because they lead to some degree of mean improvement over baseline and because of the widespread belief that their mechanisms are limited and their effects are completely reversible. Current trial methodologies cannot distinguish between symptomatic and disease-modifying effects. Furthermore, it is highly likely that many trials will demonstrate a combination of such effects at the level of the trial or at the level of the individual. ...
Subjects
free text keywords: Health Policy, Developmental Neuroscience, Epidemiology, Cellular and Molecular Neuroscience, Geriatrics and Gerontology, Psychiatry and Mental health, Clinical Neurology, Clinical trial, Disease, Symptomatic treatment, Alternative medicine, medicine.medical_specialty, medicine, Intensive care medicine, Drug development, Physical therapy, business.industry, business
Related Organizations
Any information missing or wrong?Report an Issue